{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-015770","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2023-05-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.074397+00:00","generated_at":"2026-06-14T15:10:27.696464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q4 revenue down 5.6%, AOI down 21%; FY net income down 50% to $0.9M","bullets":["Q4 revenues $55.6M, -5.6% YoY; net income $0.6M ($0.11 diluted EPS) vs net loss $1.8M prior year.","FY23 revenues $219.1M (+18.8%); core organic growth 5.2%; net income $0.9M ($0.17) -50.3% YoY.","AOI ex-unusual items Q4 $10.7M (-21.1% YoY); FY23 $45.8M (-1.7% YoY).","Clinical Genomics revenues -15.8% organic; Sema4 closure headwind ~$8.2M annually.","Management guides conservatively for FY24; sees soft CAPEX orders, expects currency headwinds to abate."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-015770","json":"https://secwatch.observer/filing/0001437749-23-015770.json","markdown":"https://secwatch.observer/filing/0001437749-23-015770.md","text":"https://secwatch.observer/filing/0001437749-23-015770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774923015770/0001437749-23-015770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774923015770/mlab20230524_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T15:10:27.696464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}